Cargando…
A multicenter non-randomized, uncontrolled single arm trial for evaluation of the efficacy and the safety of the treatment with favipiravir for patients with severe fever with thrombocytopenia syndrome
Severe fever with thrombocytopenia syndrome (SFTS) is a bunyavirus infection with high mortality. Favipiravir has shown effectiveness in preventing and treating SFTS virus (SFTSV) infection in animal models. A multicenter non-randomized, uncontrolled single arm trial was conducted to collect data on...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7899362/ https://www.ncbi.nlm.nih.gov/pubmed/33617533 http://dx.doi.org/10.1371/journal.pntd.0009103 |
_version_ | 1783654039016177664 |
---|---|
author | Suemori, Koichiro Saijo, Masayuki Yamanaka, Atsushi Himeji, Daisuke Kawamura, Masafumi Haku, Takashi Hidaka, Michihiro Kamikokuryo, Chinatsu Kakihana, Yasuyuki Azuma, Taichi Takenaka, Katsuto Takahashi, Toru Furumoto, Akitsugu Ishimaru, Toshiyuki Ishida, Masayuki Kaneko, Masahiko Kadowaki, Norimitsu Ikeda, Kenichi Sakabe, Shigetoshi Taniguchi, Tomohiro Ohge, Hiroki Kurosu, Takeshi Yoshikawa, Tomoki Shimojima, Masayuki Yasukawa, Masaki |
author_facet | Suemori, Koichiro Saijo, Masayuki Yamanaka, Atsushi Himeji, Daisuke Kawamura, Masafumi Haku, Takashi Hidaka, Michihiro Kamikokuryo, Chinatsu Kakihana, Yasuyuki Azuma, Taichi Takenaka, Katsuto Takahashi, Toru Furumoto, Akitsugu Ishimaru, Toshiyuki Ishida, Masayuki Kaneko, Masahiko Kadowaki, Norimitsu Ikeda, Kenichi Sakabe, Shigetoshi Taniguchi, Tomohiro Ohge, Hiroki Kurosu, Takeshi Yoshikawa, Tomoki Shimojima, Masayuki Yasukawa, Masaki |
author_sort | Suemori, Koichiro |
collection | PubMed |
description | Severe fever with thrombocytopenia syndrome (SFTS) is a bunyavirus infection with high mortality. Favipiravir has shown effectiveness in preventing and treating SFTS virus (SFTSV) infection in animal models. A multicenter non-randomized, uncontrolled single arm trial was conducted to collect data on the safety and the effectiveness of favipiravir in treatment of SFTS patients. All participants received favipiravir orally (first-day loading dose of 1800 mg twice a day followed by 800 mg twice a day for 7–14 days in total). SFTSV RT-PCR and biochemistry tests were performed at designated time points. Outcomes were 28-day mortality, clinical improvement, viral load evolution, and adverse events (AEs). Twenty-six patients were enrolled, of whom 23 were analyzed. Four of these 23 patients died of multi-organ failure within one week (28-day mortality rate: 17.3%). Oral favipiravir was well tolerated in the surviving patients. AEs (abnormal hepatic function and insomnia) occurred in about 20% of the patients. Clinical symptoms improved in all patients who survived from a median of day 2 to day10. SFTSV RNA levels in the patients who died were significantly higher than those in the survivors (p = 0.0029). No viral genomes were detectable in the surviving patients a median of 8 days after favipiravir administration. The 28-day mortality rate in this study was lower than those of the previous studies in Japan. The high frequency of hepatic dysfunction as an AE was observed. However, it was unclear whether this was merely a side effect of favipiravir, because liver disorders are commonly seen in SFTS patients. The results of this trial support the effectiveness of favipiravir for patients with SFTS. |
format | Online Article Text |
id | pubmed-7899362 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-78993622021-03-02 A multicenter non-randomized, uncontrolled single arm trial for evaluation of the efficacy and the safety of the treatment with favipiravir for patients with severe fever with thrombocytopenia syndrome Suemori, Koichiro Saijo, Masayuki Yamanaka, Atsushi Himeji, Daisuke Kawamura, Masafumi Haku, Takashi Hidaka, Michihiro Kamikokuryo, Chinatsu Kakihana, Yasuyuki Azuma, Taichi Takenaka, Katsuto Takahashi, Toru Furumoto, Akitsugu Ishimaru, Toshiyuki Ishida, Masayuki Kaneko, Masahiko Kadowaki, Norimitsu Ikeda, Kenichi Sakabe, Shigetoshi Taniguchi, Tomohiro Ohge, Hiroki Kurosu, Takeshi Yoshikawa, Tomoki Shimojima, Masayuki Yasukawa, Masaki PLoS Negl Trop Dis Research Article Severe fever with thrombocytopenia syndrome (SFTS) is a bunyavirus infection with high mortality. Favipiravir has shown effectiveness in preventing and treating SFTS virus (SFTSV) infection in animal models. A multicenter non-randomized, uncontrolled single arm trial was conducted to collect data on the safety and the effectiveness of favipiravir in treatment of SFTS patients. All participants received favipiravir orally (first-day loading dose of 1800 mg twice a day followed by 800 mg twice a day for 7–14 days in total). SFTSV RT-PCR and biochemistry tests were performed at designated time points. Outcomes were 28-day mortality, clinical improvement, viral load evolution, and adverse events (AEs). Twenty-six patients were enrolled, of whom 23 were analyzed. Four of these 23 patients died of multi-organ failure within one week (28-day mortality rate: 17.3%). Oral favipiravir was well tolerated in the surviving patients. AEs (abnormal hepatic function and insomnia) occurred in about 20% of the patients. Clinical symptoms improved in all patients who survived from a median of day 2 to day10. SFTSV RNA levels in the patients who died were significantly higher than those in the survivors (p = 0.0029). No viral genomes were detectable in the surviving patients a median of 8 days after favipiravir administration. The 28-day mortality rate in this study was lower than those of the previous studies in Japan. The high frequency of hepatic dysfunction as an AE was observed. However, it was unclear whether this was merely a side effect of favipiravir, because liver disorders are commonly seen in SFTS patients. The results of this trial support the effectiveness of favipiravir for patients with SFTS. Public Library of Science 2021-02-22 /pmc/articles/PMC7899362/ /pubmed/33617533 http://dx.doi.org/10.1371/journal.pntd.0009103 Text en © 2021 Suemori et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Suemori, Koichiro Saijo, Masayuki Yamanaka, Atsushi Himeji, Daisuke Kawamura, Masafumi Haku, Takashi Hidaka, Michihiro Kamikokuryo, Chinatsu Kakihana, Yasuyuki Azuma, Taichi Takenaka, Katsuto Takahashi, Toru Furumoto, Akitsugu Ishimaru, Toshiyuki Ishida, Masayuki Kaneko, Masahiko Kadowaki, Norimitsu Ikeda, Kenichi Sakabe, Shigetoshi Taniguchi, Tomohiro Ohge, Hiroki Kurosu, Takeshi Yoshikawa, Tomoki Shimojima, Masayuki Yasukawa, Masaki A multicenter non-randomized, uncontrolled single arm trial for evaluation of the efficacy and the safety of the treatment with favipiravir for patients with severe fever with thrombocytopenia syndrome |
title | A multicenter non-randomized, uncontrolled single arm trial for evaluation of the efficacy and the safety of the treatment with favipiravir for patients with severe fever with thrombocytopenia syndrome |
title_full | A multicenter non-randomized, uncontrolled single arm trial for evaluation of the efficacy and the safety of the treatment with favipiravir for patients with severe fever with thrombocytopenia syndrome |
title_fullStr | A multicenter non-randomized, uncontrolled single arm trial for evaluation of the efficacy and the safety of the treatment with favipiravir for patients with severe fever with thrombocytopenia syndrome |
title_full_unstemmed | A multicenter non-randomized, uncontrolled single arm trial for evaluation of the efficacy and the safety of the treatment with favipiravir for patients with severe fever with thrombocytopenia syndrome |
title_short | A multicenter non-randomized, uncontrolled single arm trial for evaluation of the efficacy and the safety of the treatment with favipiravir for patients with severe fever with thrombocytopenia syndrome |
title_sort | multicenter non-randomized, uncontrolled single arm trial for evaluation of the efficacy and the safety of the treatment with favipiravir for patients with severe fever with thrombocytopenia syndrome |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7899362/ https://www.ncbi.nlm.nih.gov/pubmed/33617533 http://dx.doi.org/10.1371/journal.pntd.0009103 |
work_keys_str_mv | AT suemorikoichiro amulticenternonrandomizeduncontrolledsinglearmtrialforevaluationoftheefficacyandthesafetyofthetreatmentwithfavipiravirforpatientswithseverefeverwiththrombocytopeniasyndrome AT saijomasayuki amulticenternonrandomizeduncontrolledsinglearmtrialforevaluationoftheefficacyandthesafetyofthetreatmentwithfavipiravirforpatientswithseverefeverwiththrombocytopeniasyndrome AT yamanakaatsushi amulticenternonrandomizeduncontrolledsinglearmtrialforevaluationoftheefficacyandthesafetyofthetreatmentwithfavipiravirforpatientswithseverefeverwiththrombocytopeniasyndrome AT himejidaisuke amulticenternonrandomizeduncontrolledsinglearmtrialforevaluationoftheefficacyandthesafetyofthetreatmentwithfavipiravirforpatientswithseverefeverwiththrombocytopeniasyndrome AT kawamuramasafumi amulticenternonrandomizeduncontrolledsinglearmtrialforevaluationoftheefficacyandthesafetyofthetreatmentwithfavipiravirforpatientswithseverefeverwiththrombocytopeniasyndrome AT hakutakashi amulticenternonrandomizeduncontrolledsinglearmtrialforevaluationoftheefficacyandthesafetyofthetreatmentwithfavipiravirforpatientswithseverefeverwiththrombocytopeniasyndrome AT hidakamichihiro amulticenternonrandomizeduncontrolledsinglearmtrialforevaluationoftheefficacyandthesafetyofthetreatmentwithfavipiravirforpatientswithseverefeverwiththrombocytopeniasyndrome AT kamikokuryochinatsu amulticenternonrandomizeduncontrolledsinglearmtrialforevaluationoftheefficacyandthesafetyofthetreatmentwithfavipiravirforpatientswithseverefeverwiththrombocytopeniasyndrome AT kakihanayasuyuki amulticenternonrandomizeduncontrolledsinglearmtrialforevaluationoftheefficacyandthesafetyofthetreatmentwithfavipiravirforpatientswithseverefeverwiththrombocytopeniasyndrome AT azumataichi amulticenternonrandomizeduncontrolledsinglearmtrialforevaluationoftheefficacyandthesafetyofthetreatmentwithfavipiravirforpatientswithseverefeverwiththrombocytopeniasyndrome AT takenakakatsuto amulticenternonrandomizeduncontrolledsinglearmtrialforevaluationoftheefficacyandthesafetyofthetreatmentwithfavipiravirforpatientswithseverefeverwiththrombocytopeniasyndrome AT takahashitoru amulticenternonrandomizeduncontrolledsinglearmtrialforevaluationoftheefficacyandthesafetyofthetreatmentwithfavipiravirforpatientswithseverefeverwiththrombocytopeniasyndrome AT furumotoakitsugu amulticenternonrandomizeduncontrolledsinglearmtrialforevaluationoftheefficacyandthesafetyofthetreatmentwithfavipiravirforpatientswithseverefeverwiththrombocytopeniasyndrome AT ishimarutoshiyuki amulticenternonrandomizeduncontrolledsinglearmtrialforevaluationoftheefficacyandthesafetyofthetreatmentwithfavipiravirforpatientswithseverefeverwiththrombocytopeniasyndrome AT ishidamasayuki amulticenternonrandomizeduncontrolledsinglearmtrialforevaluationoftheefficacyandthesafetyofthetreatmentwithfavipiravirforpatientswithseverefeverwiththrombocytopeniasyndrome AT kanekomasahiko amulticenternonrandomizeduncontrolledsinglearmtrialforevaluationoftheefficacyandthesafetyofthetreatmentwithfavipiravirforpatientswithseverefeverwiththrombocytopeniasyndrome AT kadowakinorimitsu amulticenternonrandomizeduncontrolledsinglearmtrialforevaluationoftheefficacyandthesafetyofthetreatmentwithfavipiravirforpatientswithseverefeverwiththrombocytopeniasyndrome AT ikedakenichi amulticenternonrandomizeduncontrolledsinglearmtrialforevaluationoftheefficacyandthesafetyofthetreatmentwithfavipiravirforpatientswithseverefeverwiththrombocytopeniasyndrome AT sakabeshigetoshi amulticenternonrandomizeduncontrolledsinglearmtrialforevaluationoftheefficacyandthesafetyofthetreatmentwithfavipiravirforpatientswithseverefeverwiththrombocytopeniasyndrome AT taniguchitomohiro amulticenternonrandomizeduncontrolledsinglearmtrialforevaluationoftheefficacyandthesafetyofthetreatmentwithfavipiravirforpatientswithseverefeverwiththrombocytopeniasyndrome AT ohgehiroki amulticenternonrandomizeduncontrolledsinglearmtrialforevaluationoftheefficacyandthesafetyofthetreatmentwithfavipiravirforpatientswithseverefeverwiththrombocytopeniasyndrome AT kurosutakeshi amulticenternonrandomizeduncontrolledsinglearmtrialforevaluationoftheefficacyandthesafetyofthetreatmentwithfavipiravirforpatientswithseverefeverwiththrombocytopeniasyndrome AT yoshikawatomoki amulticenternonrandomizeduncontrolledsinglearmtrialforevaluationoftheefficacyandthesafetyofthetreatmentwithfavipiravirforpatientswithseverefeverwiththrombocytopeniasyndrome AT shimojimamasayuki amulticenternonrandomizeduncontrolledsinglearmtrialforevaluationoftheefficacyandthesafetyofthetreatmentwithfavipiravirforpatientswithseverefeverwiththrombocytopeniasyndrome AT yasukawamasaki amulticenternonrandomizeduncontrolledsinglearmtrialforevaluationoftheefficacyandthesafetyofthetreatmentwithfavipiravirforpatientswithseverefeverwiththrombocytopeniasyndrome AT suemorikoichiro multicenternonrandomizeduncontrolledsinglearmtrialforevaluationoftheefficacyandthesafetyofthetreatmentwithfavipiravirforpatientswithseverefeverwiththrombocytopeniasyndrome AT saijomasayuki multicenternonrandomizeduncontrolledsinglearmtrialforevaluationoftheefficacyandthesafetyofthetreatmentwithfavipiravirforpatientswithseverefeverwiththrombocytopeniasyndrome AT yamanakaatsushi multicenternonrandomizeduncontrolledsinglearmtrialforevaluationoftheefficacyandthesafetyofthetreatmentwithfavipiravirforpatientswithseverefeverwiththrombocytopeniasyndrome AT himejidaisuke multicenternonrandomizeduncontrolledsinglearmtrialforevaluationoftheefficacyandthesafetyofthetreatmentwithfavipiravirforpatientswithseverefeverwiththrombocytopeniasyndrome AT kawamuramasafumi multicenternonrandomizeduncontrolledsinglearmtrialforevaluationoftheefficacyandthesafetyofthetreatmentwithfavipiravirforpatientswithseverefeverwiththrombocytopeniasyndrome AT hakutakashi multicenternonrandomizeduncontrolledsinglearmtrialforevaluationoftheefficacyandthesafetyofthetreatmentwithfavipiravirforpatientswithseverefeverwiththrombocytopeniasyndrome AT hidakamichihiro multicenternonrandomizeduncontrolledsinglearmtrialforevaluationoftheefficacyandthesafetyofthetreatmentwithfavipiravirforpatientswithseverefeverwiththrombocytopeniasyndrome AT kamikokuryochinatsu multicenternonrandomizeduncontrolledsinglearmtrialforevaluationoftheefficacyandthesafetyofthetreatmentwithfavipiravirforpatientswithseverefeverwiththrombocytopeniasyndrome AT kakihanayasuyuki multicenternonrandomizeduncontrolledsinglearmtrialforevaluationoftheefficacyandthesafetyofthetreatmentwithfavipiravirforpatientswithseverefeverwiththrombocytopeniasyndrome AT azumataichi multicenternonrandomizeduncontrolledsinglearmtrialforevaluationoftheefficacyandthesafetyofthetreatmentwithfavipiravirforpatientswithseverefeverwiththrombocytopeniasyndrome AT takenakakatsuto multicenternonrandomizeduncontrolledsinglearmtrialforevaluationoftheefficacyandthesafetyofthetreatmentwithfavipiravirforpatientswithseverefeverwiththrombocytopeniasyndrome AT takahashitoru multicenternonrandomizeduncontrolledsinglearmtrialforevaluationoftheefficacyandthesafetyofthetreatmentwithfavipiravirforpatientswithseverefeverwiththrombocytopeniasyndrome AT furumotoakitsugu multicenternonrandomizeduncontrolledsinglearmtrialforevaluationoftheefficacyandthesafetyofthetreatmentwithfavipiravirforpatientswithseverefeverwiththrombocytopeniasyndrome AT ishimarutoshiyuki multicenternonrandomizeduncontrolledsinglearmtrialforevaluationoftheefficacyandthesafetyofthetreatmentwithfavipiravirforpatientswithseverefeverwiththrombocytopeniasyndrome AT ishidamasayuki multicenternonrandomizeduncontrolledsinglearmtrialforevaluationoftheefficacyandthesafetyofthetreatmentwithfavipiravirforpatientswithseverefeverwiththrombocytopeniasyndrome AT kanekomasahiko multicenternonrandomizeduncontrolledsinglearmtrialforevaluationoftheefficacyandthesafetyofthetreatmentwithfavipiravirforpatientswithseverefeverwiththrombocytopeniasyndrome AT kadowakinorimitsu multicenternonrandomizeduncontrolledsinglearmtrialforevaluationoftheefficacyandthesafetyofthetreatmentwithfavipiravirforpatientswithseverefeverwiththrombocytopeniasyndrome AT ikedakenichi multicenternonrandomizeduncontrolledsinglearmtrialforevaluationoftheefficacyandthesafetyofthetreatmentwithfavipiravirforpatientswithseverefeverwiththrombocytopeniasyndrome AT sakabeshigetoshi multicenternonrandomizeduncontrolledsinglearmtrialforevaluationoftheefficacyandthesafetyofthetreatmentwithfavipiravirforpatientswithseverefeverwiththrombocytopeniasyndrome AT taniguchitomohiro multicenternonrandomizeduncontrolledsinglearmtrialforevaluationoftheefficacyandthesafetyofthetreatmentwithfavipiravirforpatientswithseverefeverwiththrombocytopeniasyndrome AT ohgehiroki multicenternonrandomizeduncontrolledsinglearmtrialforevaluationoftheefficacyandthesafetyofthetreatmentwithfavipiravirforpatientswithseverefeverwiththrombocytopeniasyndrome AT kurosutakeshi multicenternonrandomizeduncontrolledsinglearmtrialforevaluationoftheefficacyandthesafetyofthetreatmentwithfavipiravirforpatientswithseverefeverwiththrombocytopeniasyndrome AT yoshikawatomoki multicenternonrandomizeduncontrolledsinglearmtrialforevaluationoftheefficacyandthesafetyofthetreatmentwithfavipiravirforpatientswithseverefeverwiththrombocytopeniasyndrome AT shimojimamasayuki multicenternonrandomizeduncontrolledsinglearmtrialforevaluationoftheefficacyandthesafetyofthetreatmentwithfavipiravirforpatientswithseverefeverwiththrombocytopeniasyndrome AT yasukawamasaki multicenternonrandomizeduncontrolledsinglearmtrialforevaluationoftheefficacyandthesafetyofthetreatmentwithfavipiravirforpatientswithseverefeverwiththrombocytopeniasyndrome |